Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Papp

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
The British Journal of Dermatology|January 11, 2013
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upK A Papp, C E M Griffiths, K Gordon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 13, 2017
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasisA Blauvelt, K A Papp, H Sofen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 12, 2024
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studiesH Bachelez, C E M Griffiths, K A Papp, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
The British Journal of Dermatology|October 10, 2017
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)K A Papp, C L Leonardi, A Blauvelt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 31, 2016
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)A Menter, K A Papp, M Gooderham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Expert consensus on the systemic treatment of atopic dermatitis in special populationsD N Adam, M J Gooderham, J R Beecker, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 3, 2021
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyondJ Beecker, K A Papp, J Dutz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyK Reich, J I Silverberg, K A Papp, et al.
The British Journal of Dermatology|February 26, 2016
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisK A Papp, K Reich, C Paul, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
The British Journal of Dermatology|January 11, 2013
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upK A Papp, C E M Griffiths, K Gordon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 13, 2017
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasisA Blauvelt, K A Papp, H Sofen, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 12, 2024
Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studiesH Bachelez, C E M Griffiths, K A Papp, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
The British Journal of Dermatology|October 10, 2017
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)K A Papp, C L Leonardi, A Blauvelt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 31, 2016
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)A Menter, K A Papp, M Gooderham, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Expert consensus on the systemic treatment of atopic dermatitis in special populationsD N Adam, M J Gooderham, J R Beecker, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 3, 2021
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyondJ Beecker, K A Papp, J Dutz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyK Reich, J I Silverberg, K A Papp, et al.
The British Journal of Dermatology|February 26, 2016
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisK A Papp, K Reich, C Paul, et al.
Pageof 6